EPISODE · Apr 14, 2022 · 24 MIN
How One Alzheimer’s Drug Is Changing the U.S. Drug Approval Conversation
from Tradeoffs
After Medicare’s decision to restrict coverage of the controversial new Alzheimer’s drug Aduhelm, we look at how this one drug has forced the nation to reexamine how to balance the needs of desperate patients, incomplete evidence and larger economic realities.Guests:Phil Gutis, Alzheimer’s patient and advocateHolly Fernandez Lynch, JD, MBe, John Russell Dickson, MD Presidential Assistant Professor of Medical Ethics, University of PennsylvaniaHave a look at some additional resources and a full transcript.Support this type of journalism today, with a gift.Follow us on Twitter. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
After Medicare’s decision to restrict coverage of the controversial new Alzheimer’s drug Aduhelm, we look at how this one drug has forced the nation to reexamine how to balance the needs of desperate patients, incomplete evidence and larger economic realities.Guests:Phil Gutis, Alzheimer’s patient and advocateHolly Fernandez Lynch, JD, MBe, John Russell Dickson, MD Presidential Assistant Professor of Medical Ethics, University of PennsylvaniaHave a look at some additional resources and a full transcript.Support this type of journalism today, with a gift.Follow us on Twitter. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
How One Alzheimer’s Drug Is Changing the U.S. Drug Approval Conversation
No transcript for this episode yet
Similar Episodes
Jun 24, 2026 ·58m
Jun 23, 2026 ·45m
Jun 22, 2026 ·28m